CLINICAL POLICY: Ozempic (semaglutide)
EFFECTIVE DATE: 01/15/2025
LAST REVIEW DATE: 12/20/2024

I. INDICATIONS
Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

II. CRITERIA FOR INITIAL APPROVAL
Ozempic may be approved when ALL of the following criteria are met:
1. Diagnosis: Member has a confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) as evidenced by:
   a. Hemoglobin A1c (HbA1c) ≥ 6.5% on two separate occasions, OR
   b. Fasting plasma glucose ≥ 126 mg/dL on two separate occasions, OR
   c. Random plasma glucose ≥ 200 mg/dL with classic symptoms of hyperglycemia

2. Age: Member is ≥ 18 years of age

3. Prior Therapy: Member has tried and failed OR has a contraindication to metformin, defined as:
   a. Failure: Inadequate glycemic control (HbA1c > 7.0%) despite ≥ 3 months of maximally tolerated metformin therapy (≥ 1500 mg/day or documented intolerance to higher doses)
   b. Contraindication: One of the following:
      i. eGFR < 30 mL/min/1.73m²
      ii. History of lactic acidosis
      iii. Documented severe gastrointestinal intolerance to metformin

4. Clinical Appropriateness: Member does NOT have any of the following:
   a. Personal or family history of medullary thyroid carcinoma (MTC)
   b. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
   c. History of pancreatitis
   d. Severe gastroparesis
   e. Pregnancy or planning to become pregnant

5. Baseline Documentation: The following must be documented:
   a. Current HbA1c level (within last 90 days)
   b. Current weight/BMI
   c. Liver function tests (ALT, AST)
   d. Renal function (eGFR)

III. DURATION OF APPROVAL
Initial approval: 6 months
Renewal approval: 12 months

IV. RENEWAL CRITERIA
For renewal, the following must be demonstrated:
1. Continued diagnosis of T2DM
2. Reduction in HbA1c of ≥ 0.5% from baseline OR maintenance of HbA1c < 7.0%
3. No new contraindications have developed
4. Member is tolerating therapy without severe adverse effects
